SRPT
Sarepta Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.62Close
$2.0BMarket cap
$14.86 – $24.4552-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 40 · weaker than 60% of stocks over 12 months
- Earnings shrinking EPS −103% year on year
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
24%
1wk
up 5.0%
price change
1mo
up 2.2%
price change
12-month return
down 20%
market up 11% ·
its own down 31%
F-score
—
— Not assessed
Altman Z
-1.12
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.7×
price / book
Earnings yield
down 35.3%
EBIT / enterprise value
Cheaper than
28%
of the market · expensive
Revenue growth
up 4%
year on year
EPS growth
down 103%
latest quarter
Sales growth
down 36%
latest quarter · +10 pts
ROE
down 53%
return on equity
Free cash margin
down 16%
-$307.5M FCF
D/E
0.73
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
Repair signals
- Long-term debt down 27% ($1.1B → $0.8B)
Trade setup
ATR%
5.2%
$0.97 a day · 2×ATR $16.68
RS
40 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.78
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- 50-day average above the 150 and 200-day: passes
- Within 25% of the 52-week high: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 8.3% over the year, from 97m to 105m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+3% vs market2 sessions after results
Financials
- Net -38%
- Free cash -16%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $455.9M | $612.4M | $843.8M | $1.1B | $1.8B | $1.9B |
| Gross margin | — | — | — | — | — | 99% |
| Operating income | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$699.8M |
| Net income | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
| Net margin | -122% | -68% | -83% | -47% | 13% | -38% |
| Earnings per share | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.18 | -$7.13 |
| Free cash flow | $25.3M | -$481.7M | -$356.2M | -$577.1M | -$342.7M | -$307.5M |
| Free cash margin | 6% | -79% | -42% | -50% | -19% | -16% |
| Cash | $1.5B | $2.1B | $966.8M | $428.4M | $1.1B | $801.3M |
| Long-term debt | $992.5M | $563.7M | $1.5B | $1.2B | $1.1B | $829.0M |
| Shareholders' equity | $761.8M | $928.0M | $384.9M | $859.3M | $1.5B | $1.1B |
| Shares outstanding | 79.37m | 87.13m | 87.95m | 93.73m | 96.90m | 104.96m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 1, 2024 | Quarterly ↗ | Mar 31, 2024 | 31d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 1, 2023 | Quarterly ↗ | Sep 30, 2023 | 32d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 23, 2026 | Material agreement ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 27, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 25, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Dec 19, 2025 | Material agreement · New obligation ↗ |
| Dec 11, 2025 | Unregistered share sale · Other events ↗ |
| Dec 8, 2025 | Director or officer change ↗ |
| Nov 3, 2025 | Results ↗ |